Human LRG1
(Leucine rich alpha 2 glycoprotein-1)

Catalog No. 9050

Analysis SDS PAGE: Major ~50 kDa band on Laemmli reducing gels.

Purity ≥95%

Concentration 0.25 - 1 mg/ml (Abs 0.1% at 280 nm = 0.938)

Buffer 150 mM NaCl, 10 mM sodium phosphate, 0.09% NaN₃, pH 7.2.

Storage -20 to -80°C. Avoid repeated freeze-thaws

The polypeptide chain of human LRG1 has a molecular weight of ~34,500 Da. It is N-glycosylated at multiple sites and migrates on reducing SDS PAGE gels as a band of ~50 kDa. LRG1 is an acute phase protein. It is upregulated in the serum of patients suffering from various diseases including ovarian cancer, Kawasaki disease and rheumatoid arthritis.

Raw materials used in the manufacture of this product have been tested at the donor unit level for HbsAg, anti-HIV-1/HIV-2 and HCV Ab and all results were non-reactive.

NO TEST CAN GUARANTEE A PRODUCT TO BE NON-INFECTIOUS, THEREFORE ALL MATERIAL DERIVED FROM HUMAN FLUIDS SHOULD BE CONSIDERED AS POTENTIALLY INFECTIOUS